Boditech Med Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Boditech Med wird ein jährliches Gewinn- und Umsatzwachstum von 17.6% bzw. 13.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 15.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 16.5% betragen.

Wichtige Informationen

17.6%

Wachstumsrate der Gewinne

15.4%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	34.0%
Wachstumsrate der Einnahmen	13.1%
Zukünftige Eigenkapitalrendite	16.5%
Analystenabdeckung	Low
Zuletzt aktualisiert	24 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Boditech Med Inc. (KOSDAQ:206640) Shares Fly 49% But Investors Aren't Buying For Growth

Apr 16

Here's Why I Think Boditech Med (KOSDAQ:206640) Might Deserve Your Attention Today

Apr 13

Could The Market Be Wrong About Boditech Med Inc. (KOSDAQ:206640) Given Its Attractive Financial Prospects?

Mar 01

Boditech Med (KOSDAQ:206640) Seems To Use Debt Rather Sparingly

Jan 18

Here's Why I Think Boditech Med (KOSDAQ:206640) Is An Interesting Stock

Dec 28

Did Business Growth Power Boditech Med's (KOSDAQ:206640) Share Price Gain of 193%?

Dec 08

Boditech Med Inc. (KOSDAQ:206640) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Nov 18

Gewinn- und Umsatzwachstumsprognosen

KOSDAQ:A206640 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (KRW Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	201,400	46,200	28,300	47,100	1
12/31/2025	173,900	38,850	26,250	37,450	2
12/31/2024	158,800	37,000	26,400	38,800	1
3/31/2024	137,839	27,045	24,370	31,799	N/A
12/31/2023	134,219	25,947	28,670	34,300	N/A
9/30/2023	128,155	25,871	25,386	30,349	N/A
6/30/2023	121,041	22,609	26,367	35,776	N/A
3/31/2023	110,218	21,117	12,792	27,075	N/A
12/31/2022	118,077	24,152	6,213	23,068	N/A
9/30/2022	126,066	25,041	2,411	22,442	N/A
6/30/2022	142,187	33,340	1,790	24,706	N/A
3/31/2022	159,953	41,457	13,918	32,618	N/A
12/31/2021	157,708	44,367	31,516	49,927	N/A
9/30/2021	177,616	56,048	44,483	59,441	N/A
6/30/2021	174,334	56,018	54,358	61,535	N/A
3/31/2021	163,625	54,389	50,272	57,354	N/A
12/31/2020	144,131	45,489	40,352	44,643	N/A
9/30/2020	106,463	31,274	29,505	33,510	N/A
6/30/2020	84,712	21,267	14,159	18,069	N/A
3/31/2020	70,140	11,342	14,883	18,601	N/A
12/31/2019	72,799	11,650	12,172	17,242	N/A
9/30/2019	71,903	4,048	12,754	17,817	N/A
6/30/2019	71,815	772	8,743	14,094	N/A
3/31/2019	70,810	853	3,318	8,568	N/A
12/31/2018	66,204	-1,691	1,615	5,315	N/A
9/30/2018	62,113	-3,510	-7,339	-3,393	N/A
6/30/2018	55,175	-4,206	-6,881	-2,743	N/A
3/31/2018	52,908	-3,880	-3,736	1,648	N/A
12/31/2017	52,594	-2,148	N/A	887	N/A
9/30/2017	52,703	6,400	N/A	6,164	N/A
6/30/2017	55,832	9,627	N/A	8,619	N/A
3/31/2017	58,211	11,575	N/A	9,745	N/A
12/31/2016	54,974	12,621	N/A	11,791	N/A
9/30/2016	50,911	7,427	N/A	13,133	N/A
6/30/2016	47,053	255	N/A	13,249	N/A
3/31/2016	41,915	-589	N/A	10,116	N/A
12/31/2015	39,821	-1,970	N/A	9,632	N/A
12/31/2013	22,956	5,412	N/A	5,268	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: A206640Das prognostizierte Gewinnwachstum (20.9% pro Jahr) liegt über der Sparquote (2.5%).

Ertrag vs. Markt: A206640Die Erträge des Unternehmens (20.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt KR (28.3% pro Jahr).

Hohe Wachstumserträge: A206640Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: A206640Die Einnahmen des Unternehmens (16.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt KR (10.2% pro Jahr).

Hohe Wachstumseinnahmen: A206640Die Einnahmen des Unternehmens (16.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: A206640Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (16.5%).

Boditech Med Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

SphingoTec GmbH Introduces Kidney Function Biomarker penKid Together with Boditech Med Inc. At the 42nd AKI & CRRT Course in Vicenza

Upcoming dividend of ₩150 per share at 0.7% yield

Third quarter 2023 earnings released: EPS: ₩420 (vs ₩266 in 3Q 2022)

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 25%

Investor sentiment improves as stock rises 19%

Full year 2022 earnings released: EPS: ₩1,080 (vs ₩1,937 in FY 2021)

Investor sentiment improved over the past week

Upcoming dividend of ₩200 per share

Boditech Med Inc. (KOSDAQ:A206640) announces an Equity Buyback for KRW 5,000 million worth of its shares.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of ₩200 per share

Third quarter 2021 earnings released: EPS ₩624 (vs ₩619 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Boditech Med Inc. (KOSDAQ:206640) Shares Fly 49% But Investors Aren't Buying For Growth

Boditech Med Inc. (KOSDAQ:A206640) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Here's Why I Think Boditech Med (KOSDAQ:206640) Might Deserve Your Attention Today

Investor sentiment improved over the past week

Could The Market Be Wrong About Boditech Med Inc. (KOSDAQ:206640) Given Its Attractive Financial Prospects?

Investor sentiment deteriorated over the past week

New 90-day low: ₩18,200

Boditech Med Inc., Annual General Meeting, Mar 29, 2021

Boditech Med (KOSDAQ:206640) Seems To Use Debt Rather Sparingly

New 90-day low: ₩21,000

Here's Why I Think Boditech Med (KOSDAQ:206640) Is An Interesting Stock

Investor sentiment deteriorated over the past week

New 90-day low: ₩23,650

Did Business Growth Power Boditech Med's (KOSDAQ:206640) Share Price Gain of 193%?

New 90-day low: ₩23,950

Boditech Med Inc. (KOSDAQ:206640) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Market pulls back on stock over the past week

Market bids up stock over the past week

Choi Eui Yul and three related parties acquired 27% stake in Boditech Med Inc. (KOSDAQ:A206640).

Kim Jae Hak and 11 related parties acquired 11.66% stake in Boditech Med Inc. (KOSDAQ:A206640).

New 90-day high - ₩29,150

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken